Definium Therapeutics (DFTX) CLO Mark Sullivan Buys 62,500 Shares
Mark Sullivan, Chief Legal Officer of Definium Therapeutics, buys 62,500 shares in a notable insider transaction.
Reviewed by automated data checks against the source filing. How we make and check alerts
Mark Sullivan, Chief Legal Officer at Definium Therapeutics, Inc. ($DFTX), bought 62,500 shares on June 22, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $DFTX is up 26.9% after 1 week, up 19.1% after 1 month and down 12.5% to date (from the $36.67 close on Jun 22, 2026).
DFTX
Definium Therapeutics, Inc.
Key Points
- On June 22, 2026, Mark Sullivan, Chief Legal Officer at Definium Therapeutics, bought 62,500 shares of DFTX at a price around $36.67, totaling approximately $2.29 million.
- Definium Therapeutics has a market cap of about $5.3 billion and is focused on developing treatments for brain health disorders.
- Analysts are optimistic about the stock, with a consensus rating of 'strong buy' and a mean price target of $71.65.
Get $DFTX trade alerts by text
We text you when insiders, Congress or big funds trade $DFTX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Definium Therapeutics, Inc. alert may contain errors. Disclosures
Mark Sullivan's Notable Insider Purchase
On June 22, 2026, Mark Sullivan, the Chief Legal Officer of Definium Therapeutics, Inc. (DFTX) on the NasdaqGS, bought 62,500 shares. This purchase is valued at approximately $2.29 million based on the current price of $36.67 per share.
Insider Buying and Selling at Definium Therapeutics, Inc.
Sullivan's purchase stands out against recent insider activity at Definium. On June 25, 2026, several executives sold shares, including Sullivan himself, who sold 13,008 shares at $45.03 each, totaling around $585,750. Other executives, such as CFO Brandi Roberts and Chief Medical Officer Daniel Karlin, also sold shares on the same day, indicating mixed sentiment among the leadership.
Institutional Interest
While there are no recent changes from other funds reported, Definium Therapeutics has attracted attention from analysts. The company operates in the healthcare sector, specifically focusing on developing novel treatments for brain health disorders.
Stock Performance and Market Context
Currently, DFTX is trading at $36.67, which is significantly above its 52-week low of $9.35. This purchase by Sullivan comes at a time when the stock has shown volatility, reaching a high of $49.70 in the past year. Investors may see this purchase as a sign of confidence amidst recent insider selling.
Analysts Set New Price Targets
Analysts are generally positive on Definium. On October 9, 2026, JP Morgan initiated coverage with an 'Overweight' rating and a target price of $84. Other firms, including Canaccord Genuity and Baird, have maintained their 'Buy' and 'Outperform' ratings, with targets of $78 and $79, respectively. The consensus recommendation remains a strong buy, reflecting optimism about the company’s future.
What to Watch at Definium Therapeutics, Inc.
Investors will be looking ahead to the next earnings report scheduled for November 5, 2026. This will provide further insights into the company's financial health following recent insider transactions. Remember, Sullivan's purchase reflects a snapshot of ownership as of June 22, 2026, and may not represent current holdings.
Related Filing Alerts
Source: Mark Sullivan's Form 4 filing on $DFTX (Jun 22, 2026). Find the original filing: DFTX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts